Stocktoria
Lantheus Holdings, Inc. LNTH
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2015-06-25
Lantheus Holdings, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.5B | $1.5B | $1.3B | $935.1M | $425.2M |
| Gross profit | $942.0M | $988.3M | $709.5M | $581.7M | $187.7M |
| R&D expense | $177.3M | $168.1M | $77.7M | $311.7M | $45.0M |
| Operating income | $310.8M | $457.0M | $364.6M | $36.2M | -$60.8M |
| Interest expense | — | — | $20.0M | $7.2M | $7.8M |
| Income tax | $80.2M | $118.5M | $84.3M | -$1.3M | -$3.8M |
| Net income | $233.6M | $312.4M | $326.7M | $28.1M | -$71.3M |
| EPS (diluted) | $3.41 | $4.36 | $4.65 | $0.40 | $-1.06 |
| Operating cash flow | $390.1M | $544.8M | $305.3M | $281.8M | $53.9M |
| Cash & equivalents | $359.1M | $912.8M | $713.7M | $415.7M | $98.5M |
| Inventory | $64.7M | $68.0M | $64.0M | $35.5M | $35.1M |
| Total assets | $2.2B | $2.0B | $1.7B | $1.3B | $863.8M |
| Total liabilities | $1.1B | $892.3M | $835.3M | $874.1M | $399.3M |
| Shareholders' equity | $1.1B | $1.1B | $815.9M | $447.1M | $464.4M |
Source: SEC EDGAR filings · CIK 0001521036 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.